Original Article

Medical Oncology

, Volume 23, Issue 1, pp 91-104

First online:

Advanced colon cancer

Antiprogressive immunotherapy using an autologous hemoderivative
  • Eduardo Lasalvia-PriscoAffiliated withResearch & Development Department, PharmaBlood IncNational Institute of Oncology Email author 
  • , Emilio Garcia-GiraltAffiliated withCentre De Cancerologie Hartmann
  • , Silvia CucchiAffiliated withDepartment of Advanced Medical Treatments
  • , Jesús VázquezAffiliated withDepartment of Advanced Medical TreatmentsNational Institute of Oncology
  • , Eduardo Lasalvia-GalanteAffiliated withDepartment of Advanced Medical Treatments
  • , Wilson GolomarAffiliated withDepartment of Advanced Medical TreatmentsNational Institute of Oncology
  • , Joshemaria LarrañagaAffiliated withDepartment of Advanced Medical TreatmentsNational Institute of Oncology

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



Advanced colon cancer patients, acquired-chemotherapy resistant and in progression, are therapeutically terminal. We tested a recently described medical procedure using a thermostable autologous hemoderivative purported to inhibit tumor growth possibly through an immunological mechanism of action.

Patients and Methods

Metastatic colon cancer patients chemotherapy-resistant, high CEA plasma levels, in progression, were 2-group randomized. Group 1 received the test procedure and Group 2 adequate control measures. During an 8-mo follow-up period (n=101), tumor growth, number of cases attaining clinical nonprogressive status, and mortality were assessed monthly. Immunological effect was assessed by delayed-type hypersensitivity test and lymphocyte proliferation assay. Responding-tumors histopathologies were studied.

Results and Discussion

In a significant number of cases, the test procedure promoted inhibition of tumor growth, nonprogressive disease status, and lower cumulative mortality. These clinical results were associated with polyvalent immunization against several tested antigens: the hemoderivative used for treatment, the blood tumor markers, and the regulatory lymphocyte population (CD4+CD25+). Interference with this regulatory activity could explain the selective autoimmunity suggested by the histopathology findings in responding tumors.


The autologous hemoderivative tested is antigenically polyvalent and promotes a polytargeted immune response associated with a tumor antiprogressive effect, consequently, acting as an autologous hemoderivative cancer vaccine.

Key words

Autologous hemoderivative colon cancer vaccine